natgillin/translations-raw huggingface dataset:
The Rapporteur Member State shall, in the case of a dossier which it considers to be complete, carry out the evaluation in accordance with Article 11(2) of Directive 98/8/EC and shall prepare a report on that evaluation, hereinafter «the competent authority report».
Dersom den rapporterende medlemsstaten anser at dokumentasjonen er fullstendig, skal den foreta vurderingen i samsvar med artikkel 11 nr. 2 i direktiv 98/8/EF og utarbeide en rapport om vurderingen, heretter kalt «vedkommende myndighets rapport».
Without prejudice to Article 12 of Directive 98/8/EC, the Rapporteur Member State may take into consideration other relevant technical or scientific information regarding the properties of the active substance, metabolites or residues.
Med forbehold for artikkel 12 i direktiv 98/8/EF kan den rapporterende medlemsstaten ta hensyn til andre tekniske eller vitenskapelige opplysninger om det aktive stoffets egenskaper, metabolitter eller restkonsentrasjoner.
A participant may require the Rapporteur Member State to take into consideration additional information relating to an active substance for which the dossier has been accepted as complete only if, at the time when the dossier was submitted, the participant informed the Rapporteur Member State that preparation of the information was under way, and if:
En deltaker kan kreve at den rapporterende medlemsstaten tar hensyn til tilleggsopplysninger om et aktivt stoff som det foreligger godkjent, fullstendig dokumentasjon for, dersom deltakeren på det tidspunkt da dokumentasjonen ble innlevert, underrettet den rapporterende medlemsstaten om at opplysningene var under utarbeiding, og dersom
the information is submitted no later than nine months after acceptance of the dossier in accordance with Article 9(3);
opplysningene oversendes senest ni måneder etter at dokumentasjonen ble godkjent i samsvar med artikkel 9 nr. 3,
by comparison with the data originally submitted, the information is equally or more reliable owing to the application of the same or higher quality standards;
opplysningene er minst like pålitelige som de dataene som opprinnelig ble framlagt fordi det er anvendt tilsvarende eller høyere kvalitetsstandarder,
by comparison with the data originally submitted, the information supports a different conclusion concerning the active substance for the purposes of the recommendation under paragraph 7.
opplysningene, sammenlignet med de dataene som opprinnelig ble framlagt, fører til en annen konklusjon om det aktive stoffet med hensyn til anbefalingen omhandlet i nr. 7.
The Rapporteur Member State shall take into account additional information submitted by persons other than the participant only if that information satisfies the conditions set out in points (a), (b) and (c) of the first subparagraph.
Den rapporterende medlemsstaten skal ta hensyn til tilleggsopplysninger som er framlagt av andre enn deltakeren, bare dersom disse opplysningene oppfyller vilkårene fastsatt i bokstav a), b) og c) i første ledd.
Where relevant in the application of paragraph 1, in particular when additional information has been requested by a deadline established by the Rapporteur Member State, the latter may request that the participant submit updated summary dossiers to the Commission and the other Member States when the additional information is received.
Når det er relevant for anvendelsen av nr. 1, og særlig når det er blitt bedt om tilleggsopplysninger innen en frist fastsatt av den rapporterende medlemsstaten, kan sistnevnte anmode deltakeren om å framlegge for Kommisjonen og de andre medlemsstatene et ajourført sammendrag av dokumentasjonen når tilleggsopplysningene er mottatt.
Article 8(3), (4) and (5) shall apply mutatis mutandis if:
Artikkel 8 nr. 3
the additional information is not received by the deadline;
tilleggsopplysningene ikke er mottatt innen tidsfristen,
the participant fails to provide adequate justification for further postponing the deadline;
deltakeren ikke gir tilfredsstillende begrunnelse for at tidsfristen skal forlenges ytterligere,
The Commission shall organise, when necessary, meetings with experts from the Member States to discuss specific issues arising in the context of ongoing evaluations.
Kommisjonen skal om nødvendig organisere møter med sakkyndige fra medlemsstatene for å drøfte særskilte spørsmål som oppstår i forbindelse med de pågående vurderingene.
A Rapporteur Member State may request that the Commission include certain specific problems on the agenda of those meetings, in which case it shall provide the necessary documentation for distribution through the Commission.
En rapporterende medlemsstat kan anmode om at Kommisjonen innlemmer visse særskilte problemer på dagsordenen for disse møtene, og skal i så fall skaffe den nødvendige dokumentasjon, som deretter skal distribueres av Kommisjonen.
The Rapporteur Member State shall, without undue delay, send a copy of the competent authority report to the Commission, the other Member States and to the participant.
Den rapporterende medlemsstaten skal uten unødige forsinkelser sende en kopi av vedkommende myndighets rapport til Kommisjonen, de andre medlemsstatene og deltakeren.
A Rapporteur Member State may decide to withhold the competent authority report if the charges payable under Article 25 of Directive 98/8/EC have not been paid in full, in which case it shall inform the participant and the Commission accordingly.
En rapporterende medlemsstat kan beslutte å holde vedkommende myndighets rapport tilbake dersom gebyrene fastsatt i artikkel 25 i direktiv 98/8/EF ikke er betalt i sin helhet, og skal i så fall underrette deltakeren og Kommisjonen om dette.
The competent authority report shall be presented in a format to be recommended by the Commission and shall include one of the following:
Vedkommende myndighets rapport skal framlegges i et format som anbefales av Kommisjonen, og skal inneholde enten
a recommendation to include the existing active substance in Annex I, IA or IB to Directive 98/8/EC, stating, where appropriate, conditions for inclusion;
en anbefaling om å oppføre det eksisterende aktive stoffet i vedlegg I, I A eller I B til direktiv 98/8/EF, eventuelt med angivelse av vilkårene for oppføring, eller
a recommendation not to include the existing active substance in Annex I, IA or IB to Directive 98/8/EC, stating the reasons.
en anbefaling om ikke å oppføre det eksisterende aktive stoffet i vedlegg I, I A eller I B til direktiv 98/8/EF, med angivelse av årsakene.
Commission procedures
Kommisjonens framgangsmåter
When the Commission receives a competent authority report pursuant to Article 10(5) of this Regulation it shall, without undue delay, prepare a draft decision in accordance with Article 27 of Directive 98/8/EC.
Når Kommisjonen mottar en vedkommende myndighets rapport i samsvar med artikkel 10 nr. 5 i denne forordning, skal den uten unødig forsinkelse utarbeide et utkast til beslutning i samsvar med artikkel 27 i direktiv 98/8/EF.
Before preparing the draft decision referred to in paragraph 1, the Commission shall, when necessary in the light of the comments received on the competent authority report, organise meetings with experts from the Member States to discuss any problems remaining unresolved.
Før utkastet til beslutning nevnt i nr. 1 utarbeides, skal Kommisjonen, dersom det i lys av merknadene til vedkommende myndighets rapport er nødvendig, organisere møter med sakkyndige fra medlemsstatene for å drøfte eventuelle uløste problemer.
Where necessary and upon a request from the Commission, the Rapporteur Member State shall prepare an updated competent authority report.
Den rapporterende medlemsstaten skal om nødvendig og på anmodning fra Kommisjonen utarbeide en ajourført versjon av vedkommende myndighets rapport.
In the case of an existing active substance which, despite a recommendation for inclusion pursuant to Article 10(7) of this Regulation, still gives rise to concern, as referred to in Article 10(5) of Directive 98/8/EC, the Commission may, without prejudice to Article 12 of that Directive, take into account the finalisation of the evaluation on other existing active substances applied for the same use.
Dersom et eksisterende aktivt stoff til tross for en anbefaling om oppføring i samsvar med artikkel 10 nr. 7 i denne forordning, fortsatt gir grunn til bekymring som nevnt i artikkel 10 nr. 5 i direktiv 98/8/EF, kan Kommisjonen, med forbehold for artikkel 12 i nevnte direktiv, ta hensyn til resultatet av vurderingen av andre eksisterende stoffer som brukes til samme formål.
When a Rapporteur Member State has submitted the competent authority report in accordance with Article 10(5) of this Regulation, the report shall be made publicly available by electronic means, except for information that is to be treated as confidential in accordance with Article 19 of Directive 98/8/EC.
Når en rapporterende medlemsstat har framlagt vedkommende myndighets rapport i samsvar med artikkel 10 nr. 5 i denne forordning, skal rapporten offentliggjøres elektronisk, med unntak av opplysninger som skal behandles fortrolig i samsvar med artikkel 19 i direktiv 98/8/EF.
Where, in respect of an active substance listed in Annex II to this Regulation, the Commission presents a proposal to the European Parliament and to the Council, pursuant to Directive 76/769/EEC, for the prohibition of its placing on the market or its use, including use for biocidal purposes, in certain or all product types, the procedures provided for in this Regulation concerning that substance for use in the product type(s) concerned may be suspended pending a decision on that proposal.
Dersom Kommisjonen framlegger et forslag for Europaparlamentet og Rådet i henhold til direktiv 76/769/EØF om å forby markedsføring eller bruk av et stoff oppført i vedlegg II til denne forordning, herunder bruk av stoffet som biocid, i visse eller alle produkttyper, kan framgangsmåtene fastsatt i denne forordning med hensyn til dette stoffet og bruken av det i de aktuelle produkttypene utsettes i påvente av en beslutning om forslaget.
If a notification is accepted by the Commission, the notifier shall provide to the competent authority of the designated Rapporteur Member State all data and information necessary for the evaluation of the existing active substance with a view to its possible inclusion in Annex I or Annex IA to Directive 98/8/EC during the second phase of the review programme.
Dersom Kommisjonen godkjenner en melding, skal melderen oversende vedkommende myndighet i den utpekte rapporterende medlemsstaten alle data og opplysninger som er nødvendige for vurderingen av det eksisterende aktive stoffet med henblikk på en mulig oppføring av stoffet i vedlegg I eller vedlegg I A til direktiv 98/8/EF under annen fase av vurderingsprogrammet.
The designation shall be carried out by the Commission when the list referred to in Article 6(1)(b) of this Regulation is established».
Kommisjonen skal foreta utpekingen når listen nevnt i artikkel 6 nr. 1 bokstav b) i denne forordning er utarbeidet.»
In Article 4(4), the first three subparagraphs are deleted.
I artikkel 4 nr. 4 oppheves de første tre leddene.
Article 7 is deleted.
Artikkel 7 oppheves.
«If a notification is accepted by the Commission, the notifier shall provide to the competent authority of the designated Rapporteur Member State all data and information necessary for the evaluation of the existing active substance with a view to its possible inclusion in Annex IB to Directive 98/8/EC during the second phase of the review programme.
«Dersom Kommisjonen godkjenner en melding, skal melderen oversende vedkommende myndighet i den utpekte rapporterende medlemsstaten alle data og opplysninger som er nødvendige for vurderingen av det eksisterende aktive stoffet med henblikk på en mulig oppføring av stoffet i vedlegg I B til direktiv 98/8/EF under annen fase av vurderingsprogrammet.
EXISTING ACTIVE SUBSTANCES
eksisterende aktive stoffer
Name (EINECS and/or others)
Navn (EINECS og/eller andre)
Ergocalciferol / Vitamin D2
Kalciferol / vitamin D2
Clofenotane / DDT
Klofenotan / DDT
2-imidazol-4-ylethylamine
2-imidazol-4-yletylamin
Glycerol trinitrate
Glyceroltrinitrat
Tributyltin acetate
Tributyltinnacetat
Chlorhexidine diacetate
Klorheksidindiacetat
Allyl isothiocyanate
Allylisotiocyanat
Cetrimonium bromide / Hexadecyltrimethylammonium bromide
Cetyltrimetylammoniumbromid / heksadecyltrimetylammoniumbromid
Propane-1,2-diol
1,2-propandiol
Diphenoxarsin-10-yl oxide
Difenoksarsin-10-yloksid
Gamma-HCH or Gamma-BHC / Lindane / 1,2,3,4,5,6-hexachlorocyclohexane
Gamma-HCH eller gamma-BHC / lindan / 1,2,3,4,5,6-heksaklorcykloheksan
Sulfaquinoxaline
Sulfakinoksalin
2-phenylethanol
2-fenyletanol
Methylthioninium chloride
Metyltioniniumklorid
Chloroform / Trichloromethane
Kloroform / triklormetan
Hexachlorophene
Heksaklorofen
Bromomethane / Methyl bromide
Brommetan / metylbromid
Carbon disulfide
Karbondisulfid
Iodoform / Triiodomethane
Jodoform / trijodmetan
Trichloronitromethane
Triklornitrometan
Bornan-2-one / Campher
2-bornanon / kamfer
(3aS,6aR,7aS,8S,11aS,11bS,11cS)-1,3a,4,5,6a,7,7a,8,11,11a,11b,11c-dodecahydro-2,10-dimethoxy-3,8,11a,11c-tetramethyldibenzo[de,g]chromene-1,5,11-trione / Quassin
(3aS,6aR,7aS,8S,11aS,11bS,11cS)-1,3a,4,5,6a,7,7a,8,11,11a,11b,11c-dodekahydro-2,10-dimetoksy-3,8,11a,11c-tetrametyldibenzo[de,g]kromen-1,5,11-trion / kvassin
1,3-dibromo-5,5-dimethylhydantoin
1,3-dibrom-5,5-dimetylhydantoin
3.beta.-hydroxyurs-12-en-28-oic acid / Ursolic acid
3.beta.-hydroksyurs-12-en-28-syre / ursolsyre
Citric acid monohydrate
Sitronsyremonohydrat
2-methylpropan-1-ol
2-metylpropan-1-ol
2-chloroacetamide
2-kloracetamid
Bromoacetic acid
Bromeddiksyre
Chloroacetic acid
Kloreddiksyre
L-(+)-lactic acid
L(+)-melkesyre
p-(1,1-dimethylpropyl)phenol
p-(1,1-dimetylpropyl)fenol
Coumachlor
Difacinon
Diphacinone
Etylkininkarbonat
Dibutyl phthalate
Dibutylftalat
Salicylanilide
Salisylanilid
Symclosene
Triklorisocyanursyre
Isopulegol
Isopulegol
Guaiacol / 2-methoxyphenol
Guaiacol / 2-metoksyfenol
Biphenyl-2-ol
2-fenylfenol/bifenyl-2-ol
Butyl 4-hydroxybenzoate
Butyl-4-hydroksybenzoat
Dibenzoyl peroxide
Dibenzoylperoksid
2-ethylhexane-1,3-diol
2-etylheksan-1,3-diol
3-chloropropane-1,2-diol
3-klorpropan-1,2-diol
2,2′-[(1,1,3-trimethylpropane-1,3-diyl)bis(oxy)]bis[4,4,6-trimethyl-1,3,2-dioxaborinane]
2,2′-[(1,1,3-trimetylpropan-1,3-diyl)bis(oksy)]bis[4,4,6-trimetyl-1,3,2-dioksaborinan]
Methenamine / Hexamethylenetetramine
Metenamin / heksametylentretamin
1,1′,1″,1
1,1′,1″,1
2,2′,2″-nitrilotriethanol
2,2′,2″-nitrilotrietanol
2-ethylhexan-1-ol / Isooctanol
2-etylheksan-1-ol / isooktanol
Citronellal
Citronellal
Geraniol
Geraniol
Ethylendiamine
Etylendiamin
Chloro-acetaldehyde
Kloracetaldehyd
Ethane-1,2-diol
Etylenglykol/ 1,2-etandiol
Glyoxal
Glyoksal
Methyl formate
Metylformiat
m-Cresol
m-Kresol
Resorcinol
Resorcinol
Cyanuric acid
Cyanursyre
Ethyl formate
Etylformiat
Succinic acid
Ravsyre
Hexa-2,4-dienoic acid / Sorbic acid
2,4-heksadiensyre / sorbinsyre
Pyridine
Pyridin
2-Butoxyethanol
2-butoksyetanol
Cetrimonium chloride / Hexadecyl-trimethylammoniumchloride
Cetyltrimetylammoniumklorid / heksadecyltrimetylammoniumklorid
Undecan-2-one / Methyl-nonyl-ketone
Undekan-2-on / metylnonylketon
2,2′-(ethylenedioxy)diethanol / Triethylene-glycol
2,2′(etylendioksy)dietanol / trietylenglykol
Undec-10-enoic acid
Undekylensyre
Oleic acid
Oleinsyre
(Z)-docos-13-enoic acid
(Z)-dokos-13-en-syre
N-(2-ethylhexyl)-8,9,10-trinorborn-5-ene-2,3-dicarboximide
N-(2-etylheksyl)-8,9,10-trinorborn-5-en-2,3-dikarboksimid
1,7,7-trimethylbicyclo[2.2.1]hept-2-yl thiocyanatoacetate
1,7,7-trimetylbicyklo(2.2.1)hept-2-yltiocyanatoacetat
Linalyl acetate
Linalylacetat
3,3′,4′,5,7-pentahydroxyflavone
3,3′,4′,5,7-pentahydroksyflavon
Clorophene
Klorofen
Ethyl 4-hydroxybenzoate
Etyl-4-hydroksybenzoat
3-(but-2-enyl)-2-methyl-4-oxocyclopent-2-enyl2,2-dimethyl-3-(3-methoxy-2-methyl-3-oxoprop-1-enyl)cyclopropanecarboxylate / Cinerin II
3-(but-2-enyl)-2-metyl-oksocyklopent-2-enyl-2,2-dimetyl-3-(3-metoksy-2-metyl-3-oksoprop-1-enyl)cyklopropankarboksylat / cinerin II
2-methyl-4-oxo-3-(penta-2,4-dienyl)cyclopent-2-enyl [1R-[1.alpha.[S*(Z)],3.beta.]]-chrysanthemate / Pyrethrin I
2-metyl-4-okso-3-(penta-2,4-dienyl)cyklopent-2-enyl-[1R-[1.alfa.[S*(Z)],3.beta.]]-krysantemat / pyretrin I
2-methyl-4-oxo-3-(penta-2,4-dienyl)cyclopent-2-enyl [1R-[1.alpha.[S*(Z)](3.beta.)-3-(3-methoxy-2-methyl-3-oxoprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate / Pyrethrin II
2-metyl-4-okso-3-(penta-2,4-dienyl)cyklopent-2-enyl[1R-[1.alfa.[S*(Z)](3.beta.)]]-3-(3-metoksy-2-metyl-3-oksyprop-1-enyl)-2,2-dimetylcyklopropankarboksylat / pyretrin II
Benzethonium chloride
Benzetoniumklorid
5-nitrothiazol-2-ylamine
5-nitrotiazol-2-ylamin
Cetalkonium chloride
Cetalkoniumklorid
4-Phenylbutanone
4-fenylbutanon
Cetylpyridinium chloride
Cetylpyridinklorid
Pyridazine-3,6-diol / Maleic hydrazide
Pyridazin-3,6-diol / maleinhydrazid
Dodecylamine / Laurylamine
Dodecylamin / laurylamin
Sodium dimethylarsinate
Natriumdimetylarsenat
Exo-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol
Ekso-1,7,7-trimetylbisyclo(2.2.1)heptan-2-ol
Nitromethylidynetrimethanol
Nitrometylidyntrimetanol
Sodium N-chlorobenzenesulphonamide
Natrium-N-klorbenzensulfonamid
Tosylchloramide sodium
Natriumtosylkloramid/ Kloramin T
Potassium dimethyldithiocarbamate
Kaliumdimetylditiokarbamat
Sodium dimethyldithiocarbamate
Natriumdimetylditiokarbamat
N-chlorosuccinimide
N-klorsuksinimid
Warfarin sodium
Warfarinnatrium
Sodium pentachlorophenolate
Natriumpentaklorfenolat
Sodium 2-biphenylate
Natrium-2-bifenylat/ natriumbifenyl-2-yloksid
2,4-Dichloro-3,5-xylenol
2,4-diklor-3,5-xylenol
Methyl anthranilate
Metylantranilat
N,N-diethyl-m-toluamide
N,N-dietyl-m-toluamid
Potassium methyldithiocarbamate
Kaliummetylditiokarbamat
Metam-sodium
Metam-Na
Dipentene
Dipenten
Disodium cyanodithiocarbamate
Dinatriumcyanditiokarbamat
Benzododecinium chloride
Benzedodeciniumklorid
Miristalkonium chloride
Miristalkoniumklorid
1,3-bis(hydroxymethyl)urea
1,3-bis(hydroksymetyl)urea
2,3-dihydroxypropyl laurate
2,3-dihydroksypropyllaurat
Nabam
Nabam
Hexanoic acid
Heksansyre
Potassium oleate
Kaliumoleat
Sodium hydrogencarbonate
Natriumhydrogenkarbonat
Quinolin-8-ol
8-hydroksykinolin
Rutoside
Rutosid
Glyoxylic acid
Glyoksylsyre
Fenchlorphos
Fenklorfos
Naled
Naled
5-chlorosalicylic acid
5-klorsalisylsyre
Potassium thiocyanate
Kaliumtiocyanat
Cyanamide
Cyanamid
2-hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one
2-hydroksy-4-isopropyl-2,4,6-cykloheptatrien-1-on
6.beta.-acetoxy-3beta(.beta.-D-glucopyranosyloxy)-8,14-dihydroxybufa-4,20,22-trienolide / Scilliroside
6.beta-acetoksy-3beta(.beta.-D-glukopyranosyloksy)-8,14-dihydroksybufa-4,20,22-trienolid / scillirosid
Barium carbonate
Bariumkarbonat
3-acetyl-6-methyl-2H-pyran-2,4(3H)-dione
3-acetyl-6-metyl-2H-pyran-2,4(3H)-dion
Osalmid
Osalmid
2,6-Dimethoxy-p-benzoquinone
2,6-dimetoksy-p-benzokinon
Acridine-3,6-diamine dihydrochloride
Akridin-3,6-diamindihydroklorid
Trisodium hydrogendicarbonate / Sodium sesquicarbonate
Trinatriumhydrogendikarbonat / natriumsesquikarbonat
Silver carbonate
Sølvkarbonat
Calcium diformate
Kalsiumdiformat
Myristic acid
Myristinsyre
1-isopropyl-4-methylbicyclo[3.1.0]hexan-3-one
1-isopropyl-4-metylbicyklo[3.1.0]heksan-3-on
1,3,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione / Hypericum perforatum
1,3,4,6,8,13-heksahydroksy-10,11-dimetylfenantor[1,10,9,8-opkra]perylen-7,14-dion / Hypericum perforatum
[4-[4,4′-bis(dimethylamino)benzhydrylidene]cyclohexa-2,5-dien-1-ylidene]dimethylammonium chloride
[4-[4,4′-bis(dimetylamino)benzhydryliden]cykloheksa-2,5-dien-1-yliden]dimetylammoniumklorid
Zinc dibenzoate
Sinkdibenzoat
Methyl isothiocyanate
Metylisotiocyanat
4,4′-(4-iminocyclohexa-2,5-dienylidenemethylene)dianiline hydrochloride
4,4’-(4-iminocykloheksa-2,5-dienylidenmetylen)dianilinhydroklorid
[4-[alpha-[4-(dimethylamino)phenyl]benzylidene]cyclohexa-2,5-dien-1-ylidene]dimethylammonium chloride / Malachite green chloride
[4-[4′-bis(dimetylamino)benzyliden]cykloheksa-2,5-dien-1-yliden]dimetylammoniumklorid / malakittgrønnklorid
RS)-3-allyl-2-methyl-4-oxocyclopent-2-enyl-(1RS,3RS;1RS,3SR)-2,2-dimethyl-3-(2-methylprop-1-enyl)-cyclopropanecarboxylate (all isomers; ratio:
(RS)-3-allyl-2-metyl-4-oksocyklopent-2-enyl-(1RS,3RS;1RS,3SR)-2,2-dimetyl-3-(2-metylprop-1-enyl)-cyklopropankarboksylat (alle isomere; forhold:
1:1:1:1:1:1:1:1) / Allethrin
1:1:1:1:1:1:1:1) / alletrin
Sodium 3-(p-anilinophenylazo)benzenesulphonate / Metanil yellow
Natrium-3-(p-anilinfenylazo)benzensulfonat / metanilgult
BHC or HCH / Hexachlorocyclohexane
BHC eller HCH / heksaklorcykloheksan
Succinaldehyde
Succinaldehyd
Phthalaldehyde
Ftalaldehyd
Tetrahydro-2,5-dimethoxyfuran
Tetrahydro-2,5-dimetoksyfuran
N-[(dichlorofluoromethyl)thio]phthalimide
N-[(diklorfluormetyl)tio]ftalimid
Dichloro-N-[(dimethylamino)sulphonyl]fluoro-N-(p-tolyl)methanesulphenamide / Tolylfluanid
Diklor-N-[(dimetylamino)sulfonyl]fluor-N-(p-tolyl)metansulfenamid / tolylfluanid
Hydroxyl-2-pyridone
Hydroksyl-2-pyridon
2,6-dimethyl-1,3-dioxan-4-yl acetate
2,6-dimetyl-1,3-dioksan-4-ylacetat
Terbutryn
Terbutryn
Proflavine hydrochloride
Proflavinhydroklorid
hydroxymethyl)urea
(hydroksymetyl)urea
Copper thiocyanate
Kobbertiocyanat
Tetradonium bromide
Tetradoniumbromid
1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate / d-Tetramethrin
(1,3,4,5,6,7-heksahydro-1,3-diokso-2H-isoindol-2-yl)metyl (1R-trans)-2,2-dimetyl-3-(2-metylprop-1-enyl)cyklopropankarboksylat / d-tetrametrin
Xylenol
Xylenol
Diarsenic pentaoxide
Diarsenpentoksid
Diboron trioxide
Dibortrioksid
Silicic acid, potassium salt / Potassium silicate
Kiselsyre, kaliumsalt / kaliumsilikat
Trizinc diphosphide
Trisinkdifosfid
Trimanganese tetraoxide
Trimangantetraoksid
Cresol
Kresol
Disodium tetraborate, anhydrous
Dinatriumtetraborat, vannfritt
Disodium tetraborate decahydrate
Dinatriumtetraboratdekahydrat
Chromium trioxide
Kromtrioksid
Sodium hydrogendifluoride
Natriumhydrogenfluorid
Naphthenic acids
Naftensyrer
Ammonium hydrogendifluoride
Ammoniumhydrogendifluorid
Copper(II) chloride
Kobber(II)klorid
N,N″-bis(2-ethylhexyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediamidine dihydrochloride
N,N″-bis(2-etylheksyl)-3,12-diimino-2,4,11,13-tetraazatetradekandiamidindihydroklorid
2,4-dichlorobenzyl alcohol
2,4-diklorbenzylalkohol
Dodecylammonium acetate
Dodecylammoniumacetat
Allyl propyl disulphide
Allylpropyldisulfid
N-(3-aminopropyl)-N-dodecylpropane-1,3-diamine
N-(3-aminopropyl)-N-dodecylpropan-1,3-diamin
Tolnaftate
Tolnaftat
Bis[[4-[4-(dimethylamino)benzhydrylidene]cyclohexa-2,5-dien-1-ylidene]dimethylammonium] oxalate, dioxalate
Bis[[4-[4′-bis(dimetylamino)benzhydryliden]cykloheksa-2,5-dien-1-yliden]dimetylammonium]oksalat, dioksalat
2,2′-dithiobis[N-methylbenzamide]
2,2′-ditio-bis[N-metylbenzamid]
2,2′-[methylenebis(oxy)]bisethanol
2,2′-[metylen-bis(oksy)]bisetanol
1,2-benzisothiazol-3(2H)-one
1,2-benzisotiazol-3(2H)-on
2,2′-[(1-methylpropane-1,3-diyl)bis(oxy)]bis[4-methyl-1,3,2-dioxaborinane]
2,2′-[(1-metylpropan-1,3-diyl)bis(oksy)]bis[4-metyl-1,3,2-dioksaborinan]
2-methyl-2H-isothiazol-3-one
2-metyl-2H-isotiazol-3-on
Sulphuryl difluoride
Sulfuryldifluorid
2-Amino-3-chloro-1,4-naphthoquinone
2-amino-3-klor-1,4-naftokinon
2-chloro-N-(hydroxymethyl)acetamide
2-klor-N-(hydroksymetyl)acetamid
Troclosene sodium
Troclosennatrium
Sodium dichloroisocyanurate dihydrate
Troclosennatrium, dihydrat
Mecetronium ethyl sulphate
Mecetroniumetylsulfat
Dodecylethyldimethylammonium ethyl sulphate
Dodecyletyldimetylammoniumetylsulfat
4-isopropyl-m-cresol
4-isopropyl-m-kresol
Copper dinitrate
Kobberdinitrat
Temephos
Temefos
Oct-1-ene-3-ol
Okt-1-en-3-ol
Sodium 5-chloro-2-[4-chloro-2-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]benzenesulphonate
Natrium-5-klor-2-[4-klor-2-[[[(3,4-diklorfenyl)amino]karbonyl]amino]fenoksy]benzensulfonat
Dipyrithione
Dipyrition
Chlorhexidine dihydrochloride
Klorheksidindihydroklorid
Hexahydro-1,3,5-tris(3-methoxypropyl)-1,3,5-triazine
Heksahydro-1,3,5-tris(3-metoksypropyl)-1,3,5-triazin
4-oxo-4-[(tributylstannyl)oxy]but-2-enoic acid / Tributyltin maleate
4-okso-4-[(tributylstannyl)oksy]but-2-en-syre / tributyltinnmaleat
N-ethylheptadecafluorooctanesulphonamide
N-etylheptadekafluoroktansulfonamid
Isobutyl 4-hydroxybenzoate / Isobutyl parabene
Isobutyl-4-hydroksybenzoat / isobutylparaben